AlphaQuest LLC Acquires 26,748 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

AlphaQuest LLC lifted its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 6,911.6% during the fourth quarter, HoldingsChannel reports. The firm owned 27,135 shares of the company’s stock after purchasing an additional 26,748 shares during the quarter. AlphaQuest LLC’s holdings in Y-mAbs Therapeutics were worth $212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in YMAB. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter worth $44,000. Intech Investment Management LLC bought a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at about $133,000. SG Americas Securities LLC raised its stake in Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after acquiring an additional 4,163 shares during the period. Principal Financial Group Inc. raised its stake in Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after acquiring an additional 1,903 shares during the period. Finally, Empire Financial Management Company LLC bought a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at about $210,000. 70.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.50% of the stock is owned by company insiders.

Y-mAbs Therapeutics Trading Down 1.3 %

YMAB stock opened at $4.67 on Monday. The company’s 50 day moving average is $5.97 and its 200 day moving average is $10.10. The stock has a market cap of $211.17 million, a price-to-earnings ratio of -8.65 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a 1-year low of $4.25 and a 1-year high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the company posted ($0.02) earnings per share. As a group, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on YMAB. Bank of America lowered their price objective on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Finally, Oppenheimer began coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.30.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.